Multi-stakeholder workshop with the HMA/EMA task force on availability of authorised medicines
At this multi-stakeholder meeting, representatives of patients, consumers and healthcare professionals and pharmaceutical industry stakeholders join regulators to discuss the work of the Heads of Medicines Agencies/EMA task force on the availability of medicines and how to contribute to its deliverables. The task force was set up to to provide strategic support and advice to tackle disruptions in supply of human and veterinary medicines and ensure their continued availability.
Attendance to this workshop is by invitation only, but all those interested are welcome to follow the live broadcast . A video recording and presentations will be published after the event.
-
List item
Report - Multi-stakeholder workshop with the HMA/EMA task force on availability of authorised medicine (PDF/3.75 MB)
First published: 08/02/2019 -
List item
Agenda - Multi-stakeholder workshop with the HMA/EMA task force on availability of authorised medicines (PDF/208.47 KB)
First published: 25/10/2018
Last updated: 26/11/2018
EMA/201498/2018 -
List item
List of participants - Multi-stakeholder workshop with the HMA/EMA task force on availability of authorised medicines (PDF/94.78 KB)
First published: 23/11/2018
EMA/725241/2018 -
List item
Presentation - Workshop objectives (K. Raudsepp) (PDF/210.14 KB)
First published: 23/11/2018 -
List item
Presentation - Availability of medicines: Impact on public health (PDF/420.65 KB)
First published: 23/11/2018 -
List item
Presentation - Medicines and vaccines shortages: a global concern (F. Blanco) (PDF/866.81 KB)
First published: 23/11/2018 -
List item
Presentation - Preparing for the unexpected: when your medicine is not available anymore (F. Houyez) (PDF/1.15 MB)
First published: 23/11/2018 -
List item
Presentation - Availability of medicines: Impact on public health (E. de Vries) (PDF/1.42 MB)
First published: 23/11/2018 -
List item
Presentation - How regulators are working to improve prevention and management of availability problems (K. Raudsepp) (PDF/961.54 KB)
First published: 23/11/2018 -
List item
Presentation - Prevention and management of availability problems: An industry perspective (PDF/1.48 MB)
First published: 23/11/2018 -
List item
Presentation - Impact of Brexit on medicines availability Centrally Authorised Products (CAPs) (M. Dias, I. Claassen) (PDF/229.77 KB)
First published: 23/11/2018 -
List item
Presentation - CMDh Brexit update (L. Oliveira, H. Hurts) (PDF/515.56 KB)
First published: 23/11/2018 -
List item
Presentation - Impact of Brexit on veterinary medicines availability (L. Le Letty) (PDF/247.89 KB)
First published: 23/11/2018 -
List item
Presentation - Industry stakeholders’ perspective: Impact of Brexit on medicines availability (Y. Stewart) (PDF/284.97 KB)
First published: 23/11/2018 -
List item
Presentation - Presentation from veterinary industry EU/EEA Brexit preparedness: status and impact (R. Clayton) (PDF/379.17 KB)
First published: 23/11/2018 -
List item
Presentation - Improving reporting and monitoring: EU-wide shortage definition and metrics (B. Cuddy, A. Hansen) (PDF/471.83 KB)
First published: 23/11/2018 -
List item
Presentation - Draft guidance for industry to improve reporting and best practice (B. Escribano, E. Martinez) (PDF/693.91 KB)
First published: 23/11/2018 -
List item
Presentation - Current public communication practices by regulators on medicines availability and shortages (Y. Knudsen) (PDF/393.91 KB)
First published: 23/11/2018 -
List item
Presentation - Best practice guidance for EU authorities on public communication (J. Burgos) (PDF/545.56 KB)
First published: 23/11/2018 -
List item
Presentation - Concluding remarks and next steps (N. Wathion) (PDF/147.21 KB)
First published: 23/11/2018